Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties.
(2015) In Drug Discovery Today 20(4). p.411-421- Abstract
- Reactive oxygen species (ROS) and reactive nitrogen species (RNS) participate in pathological tissue damage. Mitochondrial manganese superoxide dismutase (MnSOD) normally keeps ROS and RNS in check. During development of mangafodipir (MnDPDP) as a magnetic resonance imaging (MRI) contrast agent, it was discovered that MnDPDP and its metabolite manganese pyridoxyl ethyldiamine (MnPLED) possessed SOD mimetic activity. MnDPDP has been tested as a chemotherapy adjunct in cancer patients and as an adjunct to percutaneous coronary intervention in patients with myocardial infarctions, with promising results. Whereas MRI contrast depends on release of Mn(2+), the SOD mimetic activity depends on Mn(2+) that remains bound to DPDP or PLED.... (More)
- Reactive oxygen species (ROS) and reactive nitrogen species (RNS) participate in pathological tissue damage. Mitochondrial manganese superoxide dismutase (MnSOD) normally keeps ROS and RNS in check. During development of mangafodipir (MnDPDP) as a magnetic resonance imaging (MRI) contrast agent, it was discovered that MnDPDP and its metabolite manganese pyridoxyl ethyldiamine (MnPLED) possessed SOD mimetic activity. MnDPDP has been tested as a chemotherapy adjunct in cancer patients and as an adjunct to percutaneous coronary intervention in patients with myocardial infarctions, with promising results. Whereas MRI contrast depends on release of Mn(2+), the SOD mimetic activity depends on Mn(2+) that remains bound to DPDP or PLED. Calmangafodipir [Ca4Mn(DPDP)5] is stabilized with respect to Mn(2+) and has superior therapeutic activity. Ca4Mn(DPDP)5 is presently being explored as a chemotherapy adjunct in a clinical multicenter Phase II study in patients with metastatic colorectal cancer. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4912947
- author
- Karlsson, Jan Olof G ; Ignarro, Louis J ; Lundström, Ingemar ; Jynge, Per and Almén, Torsten LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Drug Discovery Today
- volume
- 20
- issue
- 4
- pages
- 411 - 421
- publisher
- Elsevier
- external identifiers
-
- pmid:25463039
- wos:000354581300005
- scopus:84928718985
- pmid:25463039
- ISSN
- 1878-5832
- DOI
- 10.1016/j.drudis.2014.11.008
- language
- English
- LU publication?
- yes
- id
- 3c027041-904b-41db-96eb-14a3afadbfb5 (old id 4912947)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25463039?dopt=Abstract
- date added to LUP
- 2016-04-01 10:12:54
- date last changed
- 2022-05-05 19:48:06
@article{3c027041-904b-41db-96eb-14a3afadbfb5, abstract = {{Reactive oxygen species (ROS) and reactive nitrogen species (RNS) participate in pathological tissue damage. Mitochondrial manganese superoxide dismutase (MnSOD) normally keeps ROS and RNS in check. During development of mangafodipir (MnDPDP) as a magnetic resonance imaging (MRI) contrast agent, it was discovered that MnDPDP and its metabolite manganese pyridoxyl ethyldiamine (MnPLED) possessed SOD mimetic activity. MnDPDP has been tested as a chemotherapy adjunct in cancer patients and as an adjunct to percutaneous coronary intervention in patients with myocardial infarctions, with promising results. Whereas MRI contrast depends on release of Mn(2+), the SOD mimetic activity depends on Mn(2+) that remains bound to DPDP or PLED. Calmangafodipir [Ca4Mn(DPDP)5] is stabilized with respect to Mn(2+) and has superior therapeutic activity. Ca4Mn(DPDP)5 is presently being explored as a chemotherapy adjunct in a clinical multicenter Phase II study in patients with metastatic colorectal cancer.}}, author = {{Karlsson, Jan Olof G and Ignarro, Louis J and Lundström, Ingemar and Jynge, Per and Almén, Torsten}}, issn = {{1878-5832}}, language = {{eng}}, number = {{4}}, pages = {{411--421}}, publisher = {{Elsevier}}, series = {{Drug Discovery Today}}, title = {{Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties.}}, url = {{http://dx.doi.org/10.1016/j.drudis.2014.11.008}}, doi = {{10.1016/j.drudis.2014.11.008}}, volume = {{20}}, year = {{2015}}, }